These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 690253

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Use of Amikacin in a hospital for children: microbiological and clinical studies.
    Marget W, Reindke B, Versmold H.
    J Infect Dis; 1976 Nov; 134 SUPPL():S412-9. PubMed ID: 825592
    [Abstract] [Full Text] [Related]

  • 5. Amikacin therapy of severe infections produced by gram-negative bacilli resistant to gentamicin.
    Valdivieso M, Bodey GP.
    Am J Med Sci; 1977 Nov; 273(2):177-84. PubMed ID: 860733
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical experience with amikacin, a new aminoglycoside antibiotic.
    Theron FP, De Kock MA.
    S Afr Med J; 1977 May 21; 51(21):746-8. PubMed ID: 327583
    [Abstract] [Full Text] [Related]

  • 8. Amikacin therapy of infections in neutropenic patients.
    Valdivieso M, Feld R, Rodriguez V, Bodey GP.
    Am J Med Sci; 1975 May 21; 270(3):453-63. PubMed ID: 1108649
    [Abstract] [Full Text] [Related]

  • 9. Clinical and bacteriological evaluation of amikacin in severe gram-negative infections.
    Klastersky J, Van Beerse D, Schoutens E, De Temmerman P, Yourassowsky E.
    J Clin Pharmacol; 1976 Apr 21; 16(4):213-22. PubMed ID: 770510
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Amikacin for treatment of infections in patients with malignant diseases.
    Bodey GP, Rodriguez V, Valdivieso M, Feld R.
    J Infect Dis; 1976 Nov 21; 134 SUPPL():S421-7. PubMed ID: 993633
    [Abstract] [Full Text] [Related]

  • 15. Amikacin-resistant gram-negative bacilli: correlation of occurrence with amikacin use.
    Levine JF, Maslow MJ, Leibowitz RE, Pollock AA, Hanna BA, Schaefler S, Simberkoff MS, Rahal JJ.
    J Infect Dis; 1985 Feb 21; 151(2):295-300. PubMed ID: 3918124
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Aminoglycoside dosing in renal transplant patients. Comparison of nomogram and individualized pharmacokinetic methods in patients with shifting renal function.
    Tofte RW, Canafax DM, Simmons RL, Peterson PK.
    Ann Surg; 1982 Mar 21; 195(3):287-93. PubMed ID: 7036923
    [Abstract] [Full Text] [Related]

  • 19. Clinical efficacy of a synergistic combination of cefotaxime and amikacin against multiresistant Pseudomonas and Serratia infections.
    Maslow MJ, Simberkoff MS, Rahal JJ.
    J Antimicrob Chemother; 1985 Aug 21; 16(2):227-34. PubMed ID: 3934125
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.